Therapy-related Acute Myeloid Leukemia after the Long-term Administration of Low-dose Etoposide for Chronic-type Adult T-cell Leukemia-lymphoma: A Case Report and Literature Review

Intern Med. 2017;56(14):1879-1884. doi: 10.2169/internalmedicine.56.7763. Epub 2017 Jul 15.

Abstract

A 61-year-old woman with chronic-type adult T-cell leukemia-lymphoma (ATL) had been taking low-dose oral etoposide for progressive lymphocytosis. After taking this for 3.5 years, she was diagnosed with therapy-related acute myeloid leukemia (t-AML), with a chromosomal translocation of t (6:11) (q27; q23). She thus received remission induction therapy, consolidation therapy, and allogeneic hematopoietic stem cell transplantation. Although both t-AML and ATL were in remissive states, she died of a therapy-related infection within 1 year. We reviewed 12 reported cases of AML complicating ATL to better characterize this unusual disease. We should therefore include t-AML in the differential diagnosis when administering low-dose etoposide for ATL over a long period of time.

Keywords: ATL; HTLV-1; allogeneic hematopoietic stem cell transplantation (allo-HSCT); t-AML.

Publication types

  • Case Reports

MeSH terms

  • Etoposide / therapeutic use
  • Female
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Leukemia, Myeloid, Acute / complications*
  • Leukemia, Myeloid, Acute / genetics
  • Leukemia, Myeloid, Acute / therapy*
  • Leukemia-Lymphoma, Adult T-Cell / complications*
  • Leukemia-Lymphoma, Adult T-Cell / drug therapy*
  • Middle Aged
  • Translocation, Genetic

Substances

  • Etoposide